Todd Schlesinger, MD
Director, Clinical Research Center of the Carolinas, Charleston, SC; Clinical Assistant Professor of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC
Disclosure
Advisory Board: Served as an investigator and/or consultant for AbbVie, Almirall, Alumis, Apogee, Arcutis, Benev, Biofrontera, Bristol Myers Squibb, Crown Aesthetics, Eli Lilly, Flint Clinical, Genentech, Janssen, LEO, Pharma, Oruka, Pfizer, Regeneron, Sun Pharma, Takeda, Verrica, and UCB; served as an investigator for AbbVie, Allergan, Almirall, Alumis, Arcutis, Aslan, Biofrontera, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Concert (acquired by Sun Pharma), Cutanea Life Sciences, Dermavant Sciences, Eli Lilly, Galderma, Highlightll, Incyte, Janssen, Nimbus Therapeutics, Medicus, Novartis, Processa, Prolacta, Regeneron, Sanofi, SkinCure Oncology, Takeda, Trevi, and Verrica; is a shareholder in Bristol Myers Squibb, Chronicle Medical Software, Derma-Gene, Eli Lilly, Propedix and Remedly; has served as a consultant for Beiersdorf, Estee Lauder, Dermsquared, HTL Biotechnology, LaRoche Posay, L'Oreal, MJH Life Sciences, and RBC Consultants; and has received salary from Avant-Health.
Grant/Research Support: Served as an investigator and/or consultant for AbbVie, Almirall, Alumis, Apogee, Arcutis, Benev, Biofrontera, Bristol Myers Squibb, Crown Aesthetics, Eli Lilly, Flint Clinical, Genentech, Janssen, LEO, Pharma, Oruka, Pfizer, Regeneron, Sun Pharma, Takeda, Verrica, and UCB; served as an investigator for AbbVie, Allergan, Almirall, Alumis, Arcutis, Aslan, Biofrontera, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Concert (acquired by Sun Pharma), Cutanea Life Sciences, Dermavant Sciences, Eli Lilly, Galderma, Highlightll, Incyte, Janssen, Nimbus Therapeutics, Medicus, Novartis, Processa, Prolacta, Regeneron, Sanofi, SkinCure Oncology, Takeda, Trevi, and Verrica; is a shareholder in Bristol Myers Squibb, Chronicle Medical Software, Derma-Gene, Eli Lilly, Propedix and Remedly; has served as a consultant for Beiersdorf, Estee Lauder, Dermsquared, HTL Biotechnology, LaRoche Posay, L'Oreal
Consultant: Served as an investigator and/or consultant for AbbVie, Almirall, Alumis, Apogee, Arcutis, Benev, Biofrontera, Bristol Myers Squibb, Crown Aesthetics, Eli Lilly, Flint Clinical, Genentech, Janssen, LEO Pharma, Oruka, Pfizer, Regeneron, Sun Pharma, Takeda, Verrica, and UCB; served as an investigator for AbbVie, Allergan, Almirall, Alumis, Arcutis, Aslan, Biofrontera, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Concert (acquired by Sun Pharma), Cutanea Life Sciences, Dermavant Sciences, Eli Lilly, Galderma, Highlightll, Incyte, Janssen, Nimbus Therapeutics, Medicus, Novartis, Processa, Prolacta, Regeneron, Sanofi, SkinCure Oncology, Takeda, Trevi, and Verrica; is a shareholder in Bristol Myers Squibb, Chronicle Medical Software, Derma-Gene, Eli Lilly, Propedix and Remedly; has served as a consultant for Beiersdorf, Estee Lauder, Dermsquared, HTL Biotechnology, LaRoche Posay, L'Oreal
Speakers’ Bureau or Honoraria:
2019-present Regeneron Speaker Bureau
2019-present SUN Pharmaceuticals Speaker Bureau
2021-present Almirall Speaker Bureau
2021-present Lilly Speaker Bureau
2022-present Pfizer Speaker Bureau
2023-present Janssen Speaker Bureau
2024-present UCB Speaker Bureau
2025-present Galderma Speaker Bureau